Slide 1: Exchange filing cover letter for Investor Presentation
Shalby/SE/2024‐25/77 October 30, 2024 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com
Slide 2: Investor Presentation Q2 & H1 FY2025
Investor Presentation Q2 & H1 FY2025
Slide 3: Agenda
AGENDA 01 SHALBY GROUP QUARTERLY AND ANNUAL PERFORMANCE PERFORMANCE 02 HOSPITAL BUSINESS QUARTERLY AND ANNUAL PERFORMANCE PERFORMANCE 03 HOMECARE BUSINESS QUARTERLY PERFORMANCE 04 FRANCHISE BUSINESS QUARTERLY PERFORMANCE 05 SHALBY ACADEMY QUARTERLY PERFORMANCE 06 IMPLANT BUSINESS QUARTERLY PERFORMAN
Slide 4: Financials Snapshot Q2 FY25
Financials Snapshot Q2 FY25 Consolidated Revenue at ₹ 2,747 mn in Q2 FY25 vs ₹ 2,434 mn in Q2 FY24 Consolidated EBITDA at ₹ 398 mn in Q2 FY25 vs ₹ 581 mn in Q2 FY24 Consolidated Consolidated PBT at ₹ 137 mn in Q2 FY25 vs ₹ 426 mn in Q2 FY24 Financial Highlights Consolidated Net debt stood at Rs.2,04
Slide 5: Consolidated Performance Highlights – Q2 FY25
Consolidated Performance Highlights – Q2 FY25 Revenue (INR MN) EBITDA1 & Margin (INR MN) 2747 581 398 2434 23.9% 14.4% Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 Up 12.9% Down 31.5% 4 1. EBITDA includes other income
Slide 6: Consolidated Performance Highlights – H1 FY25
Consolidated Performance Highlights – H1 FY25 Revenue (INR MN) EBITDA1 & Margin (INR MN) 5633 1058 4834 947 21.9% 16.8% H1 FY24 H1 FY25 H1 FY24 H1 FY25 Up 16.5% Down 10.4% 5 1. EBITDA includes other income
Slide 7: Consolidated P/L & B/S – Q2 FY25
Consolidated P/L & B/S – Q2 FY25 Profit & Loss (INR Mn) Balance Sheet (INR Mn) Gross 4057 Q2 Q2 Y-o-Y Borrowings Particulars (Rs. Millions) FY25 FY24 Growth Cash & Cash 2010 Equivalents Revenue 2,747 2,434 12.9% Net Cash/(Debt) (2,047) EBITDA 398 581 (31.5%) EBITDA Margin % 14.4% 23.9% ROCE1 10.4% P
Slide 8: Hospital Business Highlights Q2 FY25
Hospital Business Highlights Q2 FY25 Global leader in Joint replacements with more than 1,50,000 surgeries Surgery Count and YoY Growth Operational Performance Q2 Q2 YoY Particulars FY255 FY24 Growth Arthroplasty Nephro & Urology In-Patient1 (Nos.) 23.907 22,652 5.54% 3140+ 17.1% 680+ 7.9% Out Patie
Slide 9: Hospital Business Highlights – Specialty Revenue Mix
Hospital Business Highlights Specialty Revenue Mix Q2 FY2024 Q2 FY20252 Others, 12% Arthroplasty, Others, 14% Arthroplasty, 34% Nephrology, 5% 42% Nephrology, 6% Neurology, 5% Neurology, 6% Orthopaedic, 7% Orthopaedic, 9% Critical Care Oncology, 11% & General Critical Care & Medicine, General Oncolo
Slide 10: Hospital Business Highlights – Payor Mix
Hospital Business Highlights Payor Mix Q2 FY2024 Q2 FY20251 Government, 21.2% Self Pay, Government, Self Pay, 34.6% 22.7% 36.4% Insurance, Insurance, 44.2% 40.9% Notes: 9 1. .Q2’FY25 numbers includes PK Healthcare performance.
Slide 11: Diversification in Revenue Mix
High Growth Business Verticals Healthcare Conglomerate Building An Integrated Orthopedic Solutions Ecosystem Multi-Specialty Franchise Implant 11 Hospitals across western, northern 5 Hospital network USA based Knee & Hip and central India Manufacturing facility Synergistic Sustainable Business Model
Slide 12: A Legend and Visionary Doctorpreneur behind Shalby
A Legend and Visionary Doctorpreneur behind Shalby Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated “Zero Technique” that revolutionized Joint Replacement Surgery. A visionary entrepreneur, he transformed Shalby from a 6 bedded hospital in 199
Slide 13: Standalone Performance (Hospital Business)
STANDALONE PERFORMANCE (Hospital Business) 12
Slide 14: Standalone Business Highlights – Q2 FY25
Standalone Business Highlights – Q2 FY25 Financial Performance Revenue (INR Mn) EBITDA & Margin (INR Mn) 575 2228 2176 408 25.8% 18.7% Q2 FY24 Q2 FY25 Q2 FY24 Q2 FY25 Down 2.4% Down 29.1% PBT & Margin (INR Mn) ROCE (%) 473 18% 16% 283 15% 21.2% 12.9% Q2 FY24 Q2 FY25 FY 23 FY 24 H1 FY25 (Annualised)
Slide 15: Standalone Business Highlights – H1 FY25
Standalone Business Highlights – H1 FY25 Financial Performance Revenue (INR Mn) EBITDA & Margin (INR Mn) 4392 4580 1072 990 24.4% 21.6% H1 FY24 H1 FY25 H1 FY24 H1 FY25 Up 4.2% Down 7.7% PBT & Margin (INR Mn) PAT & Margin (INR Mn) 873 566 743 479 19.8% 16.2% 12.8% 10.4% H1 FY24 H1 FY25 H1 FY24 H1 FY2
Slide 16: Standalone P&L and B/S – Q2 FY25
Standalone P&L and B/S – Q2 FY25 Profit & Loss (INR Mn) Total Revenue to EBITDA 120.0% Q2 Q2 Particulars (Rs Mn) FY25 FY24 YoY Growth 100.0% 18.7% EBITDA 25.8% 80.0% Materials and 24.3% Consumables Total Revenue 2,176 2,228 (2.4%) 23.9% 60.0% Fees to Doctors and Consultants 25.8% 40.0% 23.3% Employe
Slide 17: Standalone Business CAGR Growth
Standalone Business CAGR Growth Shalby Continued to deliver high double-digit growth over the last 2 decades Revenue (INR Mn) EBITDA (INR Mn) 8504 1982 6598 1426 3284 778 1685 439 194 22 FY 2007 FY 2012 FY 2017 FY 2022 FY 2024 FY 2007 FY 2012 FY 2017 FY 2022 FY 2024 16
Slide 18: Shalby Sanar Q2'FY25 Highlights
Shalby Sanar Q2’FY25 Highlights Total IP Count Employees 22500+ ARPOB 1110+ Sanar 370+ Patients Total ₹85,722 International Expertise Served in Revenue 54% in Liver, Doctors & Centres :- Consultant FY23-24 of ₹25.74 OP Count revenue Total Bed Kidney, Ethiopia 50+ Cr. in ALOS 3.64 3820+ generated Cap
Slide 19: Homecare Business Highlights Q2 FY 2025
Homecare Business Highlights Q2 FY 2025 Q2 FY2025 Highlights Patients Served (Nos) Patients Served 9,080 in Q2 FY25 v/s 7,870 patients in Q2 FY24, grew by 15.3% YoY 9080 7,870 Revenue booked Rs.38.89 mn during Q2 FY25 v/s Rs.36.47 mn during Q2 FY24, grew by 6.6% YoY Physio, Diagnostics and Pharmacy
Slide 20: Clinical Update And Research Across Units during Q2 FY25
Clinical Update And Research Across Units during Q2 FY25 ❖ Our commitment towards augmenting Shalby’s medical program has made notable strides in advancing our growth initiative from single-specialty to multi-specialty by various brand awareness campaign , through digital platform and other various
Slide 21: Key Focus Areas For Future In Hospital business
Key Focus Areas For Future In Hospital business Global Leader in Joint Replacement with diversification in other specialties • Continue to maintain global leadership in joint replacements • Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Tra
Slide 22: Franchise Business
SHALBY ORTHOPEDICS CENTRE OF EXCELLENCE** FRANCHISE BUSINESS Build Health & Wealth » 21
Slide 23: Leveraging Expertise Through Franchise Asset Light Model
Leveraging Expertise Through Franchise Asset Light Model Franchise model will leverage Shalby expertise and enable to penetrate faster across pan-India Business models SOCE Performance in Q2 FY25 Franchise Owned – Shalby Operated (FOSO) Revenue (in ₹ mn) FOSO FOSM Total 1. The franchise is responsib
Slide 24: Shalby Academy
SHALBY ACADEMY 23
Slide 25: Shalby Academy Q2 FY25 highlights
Shalby Academy Q2 FY25 highlights Students Enrolled (In Nos) 1. Around 1135 new students registered in Q2 FY24-25 in various disciplines like Physiotherapy, Nursing, Lab Technician Nutrition & and dietetics, Clinical, Paramedics, Hospital Management, and Pharmacy as 2,062 part of their academic outr
Slide 26: Implant Business
IMPLANT BUSINESS wine
Slide 27: Diversified into Knee and Hip Implant Manufacturing In California, USA
Diversified into Knee and Hip Implant Manufacturing In California, USA Backward integration in Orthopedics with Inhouse capacity to consume in India 80,000+ Vertically integrated In- Components High Quality US FDA house manufacturing Manufacturing Approved Implants Facility capacity Surgeon’s Traini
Slide 28: Implant Business Performance Q2 FY25
Implant Business Performance Q2 FY25 Total Constructs EBITDA Revenue Sold Q2’FY25 Rs. 278 mn Rs. (7.28) mn 3,175+ Q2’FY24 Rs. 147 mn Rs. 2.31 mn 2,170+ Geographical Sales Mix USA Customer Sales Mix Product Sales Mix Wholesale, Hip USA, 30% 16% 46% India, 70% Retail, 54% Knee 84% 27
Slide 29: SAT 4 Pillars for FY2024-25
SAT 4 PILLARS FOR FY2024-25 SAT STRATEGY FOR FY2024-25 • New products Looking for another launch from 8 Mn$ through the Significantly lower Multi-vendor COGS across scratch. right products supply system • Improvement portfolio by across SEA with higher in the current (Malaysia), LATAM improving effi
Slide 30: Implant Business Roadmap
Implant Business Roadmap Shalby Advanced Technologies plans to become a Global player in a phased manner Existing Phase 1 Phase 2 Phase 3 Market Latin America Middle East Countries East Africa North America • Argentina • UAE • Kenya • Columbia • Saudi Arabia • Ethiopia Japan South-East and North • O
Slide 31: About Shalby
ABOUT SHALBY 30
Slide 32: Shalby At A Glance
Shalby At A Glance OPD clinics Presence 16 60 23 Orthopedic Implant Hospitals1 Domestic International2 Manufacturing in USA 30 Strength 2,350+ 4,600+ 1,150+ Years of Legacy Bed Capacity Total Employees3 Doctors4 Team Clinical Excellence #1 30+ ~3.3 million+ 150,000+ Global Ranking in Specialties Pat
Slide 33: 30 Years of ELITE Legacy
30 Years of ELITE Legacy Integrity Highest standards of transparency accountability, and corporate governance Learning Team-Work Laser sharp focus on A patient-centric focused upgrading the skills of team with a great blend of our team and building experience, diversity, fresh people capability thin
Slide 34: Our Journey & Expansion Plan
Our Journey & Expansion Plan • Sanar, Gurugram 130 beds • Jaipur Shalby, Jaipur (237 beds) • Acquired 100% • Naroda Shalby, Ahmedabad (267 beds) Vijay Shalby, Ahmedabad • Vapi Shalby, Vapi (146 beds) stake in Healers • • Surat Shalby, Surat (243 beds) • Lucknow SOCE, 40 beds 27 beds • Krishna Shalby
Slide 35: Hospitals Portfolio
Hospitals Portfolio Multispecialty Units (Owned and Operate) SG Shalby Vapi Shalby Indore Shalby Jaipur Shalby Krishna Shalby Mohali Shalby Naroda Shalby Jabalpur Shalby Surat Shalby Sanar Shalby 34
Slide 36: Franchise Hospital Portfolio
Franchise Hospital Portfolio Shalby Orthopedics Centre of Excellence (SOCE) Multispecialty Vijay Shalby Lucknow Shalby Zynova Shalby (Mumbai) (Shalby Operated) (Shalby Operated) (Shalby Managed) Rajkot Shalby Gwalior Shalby Ranchi Shalby (Shalby Operated) (Shalby Managed) (Shalby Managed) 35
Slide 37: Biggest Healthcare Corporate Group in Western and Central India
Biggest Healthcare Corporate Group in Western and Central India Domestic Presence…... PUNJAB ▪ Mohali – 145 beds Uttar Pradesh ▪ Lucknow – 40 beds DELHI ▪ Gurugram – 130 beds RAJASTHAN ▪ Jaipur – 237 beds Jharkhand GUJARAT Ranchi – 60 beds ▪ Ahmedabad o SG – 201 beds o Krishna – 220 beds o Naroda –
Slide 38: Sustainability Initiatives
Sustainability Initiatives ESG Mindset “We at Shalby are embracing sustainability to drive new values to our business” Community Connect 410+ Healthcare Camps Trainings Healthcare Awareness Programs Workplace Wellness 24750+ Life impacted 850+ and 830+ Man Hours Clinical and Non-Clinical training 16
Slide 39: Shalby Awards and Accolades in Q2'FY25
Shalby Awards and Accolades in Q2’FY25 News18 Rajasthan Award for Onco- Economic Times Award for Hospital TOI - Times healthcare leaders - 2024 to SG TIMES Healthcare leaders - Service Sciences to Jaipur Shalby Chain of the Year West to Shalby Multi & Krishna Shalby Excellence in Comprehensive Cance
Slide 40: Experienced Board Of Directors
Experienced Board Of Directors Dr. Ashok Bhatia Mr. Tej Malhotra Ms. Sujana Shah Independent Independent Independent Director Director Director Dr. Ashok Bhatia, a senior pharma professional has Mr. Malhotra boasts four decades of international and Mrs. Sujana Shah, a practicing Chartered Accountant
Slide 41: Disclaimer and Contact Details
DISCLAIMER and CONTACT DETAILS No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as